

Snapshot audit of the Mesothelioma Patient Caseload at the University Hospitals of Leicester (UHL) and the role of the Mesothelioma UK Nurse Specialists

Louise Nelson – Mesothelioma UK CNS UHL

Laura Smith – Mesothelioma CNS

Liz Darlison – Mesothelioma Nurse Consultant UHL

Prof D Fennell – Professor of Thoracic Oncology UHL



INTRODUCTION

A snapshot audit of the Mesothelioma patient caseload at the University Hospitals of Leicester (UHL) to demonstrate the impact of clinical trials on patients and the role of the Mesothelioma UK Nurse specialist in supporting these patients.




METHODS

Data capture was taken on 15/11/2022 and a detailed analysis of the caseload database at this time was undertaken to identify

- Total number of patients in the caseload at the time of the audit
- Number of patients who have taken part in 1 or more clinical trials and survival data
- Details of where in the UK the patients have travelled from
- Role of the Mesothelioma UK nurse in supporting these patients


This map demonstrates that Mesothelioma patients from across the United Kingdom are willing to travel to UHL in Leicester to access treatment as part of a clinical trial



RESULTS


At the time of the audit there were 90 patients with mesothelioma who were receiving treatment and care at the UHL. Whilst the majority of patients were referred in 2021 & 2022, there are some patients who were referred as early as 2013. Patients who wish to take part in clinical trials are discussed at the weekly MDT. Following the MDT decision, the Mesothelioma UK nurses provide valuable advice and support for the patients and carers to help them decide if treatment within a clinical trial is suitable for them.

Number of patients still on treatment or follow up care since they were first seen



Of these 90 patients 60% have taken part in at least 1 clinical trial and 12% have received treatment as part of 2 or more clinical trials.

Details of the trials patients have taken part in are detailed below



CONCLUSIONS

Patients are motivated to travel to seek a specialist opinion and explore clinical trial treatment options. Having Clinical trials embedded into the treatment pathway appears to have a significant impact on survival, with 15.5% of patients exceeding > 5 year survival. Co-ordinating patient pathways and providing necessary care and support is vital, this creates a measurable workload for the Mesothelioma CNS team. Entries in the electronic patient records quantify the impact the patient caseload has on the mesothelioma CNS team. Comments below from patients reflect the support they have received from the Mesothelioma CNS team

I am taking part in the Nero trial and I was worried about not getting any treatment. The Mesothelioma UK Nurses were so understanding, supportive and explained everything. I agreed to go on the trial

The Mesothelioma UK nurses supported me, by answering all my questions, to decide if the trial was the right option for me

After having chemotherapy I had been told palliative care was my only option. Being referred to Leicester and being offered treatment in a trial gave me hope

As part of the trial I have a CT scan done the same day as my clinic appointment. My Mesothelioma UK Nurse rings me with the result to avoid the anxiety of waiting 3 weeks for the result. This means I can enjoy my life between appointments



We would like to thank the following for their help in developing this poster.
Beth Colbert – Mesothelioma UK
Molly Scotland – Hope Clinical Trials Unit UHL
The Hope Clinical Trials Centre – UHL

Mesothelioma UK is the national charity for anyone affected by mesothelioma. Mesothelioma UK Charitable Incorporated Organisation is a registered charity in England & Wales (1177039)

info@mesothelioma.uk.com
www.mesothelioma.uk.com

